{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:22:12Z","timestamp":1792729332992,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacl.2026.09.009","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:49:02Z","timestamp":1789746542000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Does the evidence support the ACC\/AHA multisociety recommendation to measure apoB only after LDL-C and non\u2013HDL-C are at target?"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0278-4094","authenticated-orcid":false,"given":"Justine","family":"Cole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6923-8517","authenticated-orcid":false,"given":"Line","family":"Dufresne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5810-5460","authenticated-orcid":false,"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Langlois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Thanassoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3540-3956","authenticated-orcid":false,"given":"Allan D.","family":"Sniderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2026.09.009_bib1","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.09.009_bib2","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.09.009_bib3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/CIRCULATIONAHA.117.032463","article-title":"Impact of novel low-density lipoprotein-cholesterol assessment on the utility of secondary non-high-density lipoprotein-C and apolipoprotein B targets in selected worldwide dyslipidemia guidelines","volume":"138","author":"Sathiyakumar","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.09.009_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2021.100203","article-title":"Utility of non-HDL-C and apoB targets in the context of new more aggressive lipid guidelines","volume":"7","author":"Quispe","year":"2021","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.09.009_bib5","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile","volume":"310","author":"Martin","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2026.09.009_bib6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/clinchem\/hvac161","article-title":"A translational tool to facilitate use of apolipoprotein B for clinical decision-making","volume":"69","author":"Cole","year":"2023","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2026.09.009_bib7","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/CIRCULATIONAHA.125.077998","article-title":"Prevalence of apolipoprotein B and LDL cholesterol discordance: insights from the VLDbL and NHANES","volume":"153","author":"Peng","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.09.009_bib8","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1093\/eurheartj\/ehae258","article-title":"Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention","volume":"45","author":"Sniderman","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.09.009_bib9","first-page":"844","article-title":"ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk","volume":"19","author":"Sehayek","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.09.009_bib10","article-title":"Concordance of apolipoprotein B concentration with the Friedewald, Martin-Hopkins, and Sampson formulas for calculating LDL cholesterol","volume":"32","author":"Briers","year":"2022","journal-title":"Biochem Med (Zagreb)"},{"key":"10.1016\/j.jacl.2026.09.009_bib11","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jama.2026.2986","article-title":"Cost-effectiveness of ApoB, non-HDL-C, and LDL-C goals for primary prevention lipid-lowering therapy","volume":"335","author":"Luebbe","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2026.09.009_bib12","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.jacc.2024.03.423","article-title":"Excess apolipoprotein B and cardiovascular risk in women and men","volume":"83","author":"Johannesen","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.09.009_bib13","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-026-02928-z","article-title":"Excess apolipoprotein B predicts long-term survival in statin-treated CAD irrespective of achieved LDL-C levels: a pooled cohort analysis","volume":"25","author":"Pan","year":"2026","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacl.2026.09.009_bib14","doi-asserted-by":"crossref","DOI":"10.1186\/s12944-025-02852-8","article-title":"Association of apolipoprotein B and excess apolipoprotein B with cardiovascular risk in type 2 diabetes: a prospective cohort study of the UK Biobank","volume":"25","author":"Lyu","year":"2026","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacl.2026.09.009_bib15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00392-025-02767-5","article-title":"Association of apolipoprotein B, excess apolipoprotein B and apoB\/apoA1 ratio with 20-year atherosclerotic cardiovascular disease risk: the ATTICA study (2002-2022)","volume":"115","author":"Giannakopoulou","year":"2026","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jacl.2026.09.009_bib16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/CIRCULATIONAHA.124.068885","article-title":"Apolipoprotein B: bridging the gap between evidence and clinical practice","volume":"150","author":"De Oliveira-Gomes","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.09.009_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119139","article-title":"Discordance analyses comparing LDL cholesterol, Non-HDL cholesterol, and apolipoprotein B for cardiovascular risk estimation","volume":"403","author":"Johannesen","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.09.009_bib18","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamacardio.2024.1310","article-title":"Individual variation in the distribution of apolipoprotein B levels across the spectrum of LDL-C or non-HDL-C levels","volume":"9","author":"Sayed","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2026.09.009_bib19","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1016\/j.jacl.2024.08.013","article-title":"Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An expert clinical consensus from the national lipid association","volume":"18","author":"Soffer","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.09.009_bib20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jacl.2007.12.006","article-title":"Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice","volume":"2","author":"Sniderman","year":"2008","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.09.009_bib21","article-title":"Efficacy and safety of proprotein convertase subtilisin\/kexin type 9 inhibitors as adjuvant treatments for patients with hypercholesterolemia treated with statin: a systematic review and network meta-analysis","volume":"13","author":"Huang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacl.2026.09.009_bib22","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jacl.2023.05.093","article-title":"Is hypertriglyceridemia a reliable indicator of cholesterol-depleted Apo B particles?","volume":"17","author":"De Marco","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.09.009_bib23","article-title":"Apolipoprotein B-low-density lipoprotein cholesterol discordance refines cardiovascular risk stratification across metabolic phenotypes","volume":"S1933-2874","author":"Kim","year":"2026","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.09.009_bib24","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030405","article-title":"Standardization of apolipoprotein B, LDL-cholesterol, and non-HDL-cholesterol","volume":"12","author":"Contois","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2026.09.009_bib25","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1093\/jalm\/jfae057","article-title":"ADLM guidance document on the measurement and reporting of lipids and lipoproteins","volume":"9","author":"Cao","year":"2024","journal-title":"J Appl Lab Med"},{"key":"10.1016\/j.jacl.2026.09.009_bib26","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1515\/cclm-2019-1253","article-title":"Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM","volume":"58","author":"Langlois","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jacl.2026.09.009_bib27","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/clinchem\/hvag038","article-title":"Poor performance of LDL-cholesterol equations versus beta quantification in a very large cohort of patients with dyslipidemia","volume":"72","author":"Paquette","year":"2026","journal-title":"Clin Chem"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426005209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426005209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:24:29Z","timestamp":1792009469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426005209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"alternative-id":["S1933287426005209"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.09.009","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does the evidence support the ACC\/AHA multisociety recommendation to measure apoB only after LDL-C and non\u2013HDL-C are at target?","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}